Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

DMK

DMK Pharmaceuticals Corp

Dec 01 • 04:00PM ET

0.5677

Dollar change +0.0258
Percentage change 4.76	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-9.18	Insider Own	9.98%	Shs Outstand	10.10M	Perf Week	11.38%
Market Cap	5.73M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	9.09M	Perf Month	15.27%
Income	-22.23M	PEG	-	EPS next Q	-	Inst Own	2.44%	Short Float / Ratio	1.02% / 0.08	Perf Quarter	-28.23%
Sales	3.62M	P/S	1.58	EPS this Y	-	Inst Trans	-0.59%	Short Interest	0.09M	Perf Half Y	-72.57%
Book/sh	-0.52	P/B	-	EPS next Y	-	ROA	-200.59%	Target Price	105.00	Perf Year	-95.94%
Cash/sh	0.66	P/C	0.86	EPS next 5Y	-	ROE	-784.96%	52W Range	0.45 - 21.70	Perf YTD	-95.21%
Dividend	-	P/FCF	-	EPS past 5Y	27.79%	ROI	-	52W High	-97.38%	Beta	1.20
Dividend %	-	Quick Ratio	0.54	Sales past 5Y	13.88%	Gross Margin	-52.56%	52W Low	26.02%	ATR	0.05
Employees	11	Current Ratio	0.58	Sales Q/Q	-99.40%	Oper. Margin	-519.35%	RSI (14)	54.86	Volatility	10.02% 7.92%
Optionable	No	Debt/Eq	-	EPS Q/Q	90.43%	Profit Margin	-614.21%	Rel Volume	0.10	Prev Close	0.54
Shortable	Yes	LT Debt/Eq	-	Earnings	Nov 14 BMO	Payout	-	Avg Volume	1.23M	Price	0.57
Recom	3.00	SMA20	10.60%	SMA50	1.80%	SMA200	-84.90%	Volume	125,040	Change	4.76%

Date	Action	Analyst	Rating Change	Price Target Change
May-13-20	Upgrade	Maxim Group	Hold → Buy	$1.50
Feb-27-20	Downgrade	Dawson James	Buy → Neutral
Nov-26-19	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-16-19	Downgrade	B. Riley FBR	Neutral → Sell	$1.90 → $1.10
Nov-12-18	Downgrade	B. Riley FBR	Buy → Neutral	$7.50 → $2.50
May-11-18	Reiterated	Maxim Group	Buy	$5 → $10
Mar-23-18	Reiterated	B. Riley FBR, Inc.	Buy	$6.25 → $7.50
Dec-05-17	Reiterated	Maxim Group	Buy	$13 → $14
Oct-04-17	Resumed	B. Riley & Co.	Buy	$9.50
Jul-21-16	Reiterated	Maxim Group	Buy	$17 → $10
Dec-01-15	Initiated	Maxim Group	Buy	$16
May-29-15	Initiated	Mizuho	Buy	$10
Jan-28-14	Initiated	CRT Capital	Buy	$15

Show Previous Ratings

Nov-28-23 08:05AM	DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI and Provides Corporate Update (GlobeNewswire) +7.40%
Nov-14-23 07:30AM	DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-13-23 10:52AM	DMK Pharmaceuticals Announces Presentation of Preclinical Results Comparing Effects of DPI-125 on Opioid Withdrawal Behaviors Versus Standard of Care for Opioid Use Disorder at SfN Neuroscience 2023 (GlobeNewswire) +8.15%
Oct-30-23 07:30AM	DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-20-23 04:15PM	DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:05PM	Loading…
Oct-19-23 04:05PM	DMK Pharmaceuticals Restructures Executive Team to Support Next Phase of Growth (GlobeNewswire)
Sep-07-23 12:00PM	Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus (GlobeNewswire)
Aug-21-23 09:21AM	Adamis: Q2 Earnings Snapshot (AP Finance)
09:15AM	Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-04-23 01:43PM	Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering (GlobeNewswire) -18.18%
Aug-02-23 08:30AM	Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering (GlobeNewswire) -66.67%
Jul-28-23 08:30AM	Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert (GlobeNewswire) -13.58%
Jun-26-23 07:30AM	Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder (GlobeNewswire) +11.27%
Jun-22-23 07:30AM	Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention (GlobeNewswire) +6.32%
May-25-23 04:26PM	Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals (GlobeNewswire) -9.75%
12:00PM	Loading…
May-19-23 12:00PM	Adamis Pharmaceuticals Announces Reverse Stock Split (GlobeNewswire) -26.47%
May-16-23 06:26AM	Q1 2023 Adamis Pharmaceuticals Corp Earnings Call (Thomson Reuters StreetEvents)
May-15-23 04:47PM	Adamis: Q1 Earnings Snapshot (AP Finance) -11.39%
04:47PM	Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-23 04:05PM	Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update (GlobeNewswire)
Mar-19-23 10:33PM	Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-17-23 08:40AM	Q4 2022 Adamis Pharmaceuticals Corp Earnings Call (Thomson Reuters StreetEvents) -8.94%
Mar-16-23 04:24PM	Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-14-23 04:01PM	Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update (GlobeNewswire) -9.64%
08:30AM	Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering (GlobeNewswire)
Feb-28-23 08:22AM	Opioid Focused Adamis Pharma Agrees To Merge With Privately Held DMK Pharmaceuticals (Benzinga) -14.69%
Feb-27-23 04:05PM	Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger (GlobeNewswire) -5.22%
Feb-22-23 04:01PM	Nasdaq Grants Adamis Pharmaceuticals Request for Extension to Comply with Continued Listing Requirements (GlobeNewswire)
Dec-29-22 06:02AM	Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Q3 2022 Earnings Call Transcript (Insider Monkey)
Nov-14-22 04:10PM	Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +16.05%
04:05PM	Loading…
Nov-07-22 04:05PM	Adamis Pharmaceuticals Schedules Third Quarter 2022 Financial Results Conference Call and Corporate Update (GlobeNewswire)
Oct-04-22 06:27AM	Adamis Pharmaceuticals Seeks Strategic Options, Including Sale (Benzinga) -5.21%
Oct-03-22 04:30PM	Adamis Announces Review of Strategic Alternatives (GlobeNewswire) -16.83%
Sep-21-22 09:58AM	Adamis Pharma Shares Nosedive As Its COVID-19 Candidate Shows No Efficacy (Benzinga) -28.26%
07:30AM	Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects (GlobeNewswire)
Sep-12-22 04:05PM	Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects (GlobeNewswire) +9.08%
Aug-12-22 05:00PM	Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders (GlobeNewswire) -5.26%
Aug-10-22 04:02PM	Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-08-22 07:30AM	Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update (GlobeNewswire)
Jul-29-22 08:00AM	Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals Stockholders Vote FOR Critical Proposals at Upcoming Annual Meeting (GlobeNewswire)
07:30AM	Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19 (GlobeNewswire)
Jul-21-22 07:30AM	Adamis Pharmaceuticals Issues Letter to Stockholders (GlobeNewswire) -16.70%
Jun-01-22 08:00AM	Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19 (GlobeNewswire) -9.28%
May-31-22 12:00PM	What Makes Adamis (ADMP) a New Buy Stock (Zacks) +5.21%
May-26-22 04:05PM	Adamis Appoints Vickie Reed to Board of Directors (GlobeNewswire) +7.82%
May-18-22 05:00PM	Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth (GlobeNewswire)
May-16-22 04:35PM	Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +20.71%
May-09-22 05:56PM	Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update (GlobeNewswire) -5.82%
07:17AM	5 Winning Stocks to Land on the Overlooked Rising P/E Trick (Zacks)
Mar-31-22 04:49PM	Adamis Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
04:14PM	US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI Naloxone Product (GlobeNewswire)
Mar-30-22 05:15PM	Acutus Medical, Inc. (AFIB) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Mar-29-22 08:15PM	Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Mar-28-22 05:25PM	Ayala Pharmaceuticals, Inc. (AYLA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Mar-24-22 07:30AM	Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call and Business Update (GlobeNewswire)
Mar-22-22 07:30AM	Adamis Pharmaceuticals Announces Results of Tempol in Omicron Virus Challenge in Hamster Model (GlobeNewswire)
Mar-21-22 04:05PM	Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (epinephrine) Injection for Potential Manufacturing Defect (GlobeNewswire)
Mar-14-22 08:17AM	Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19 (GlobeNewswire) -6.10%
Mar-04-22 07:30AM	Adamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the Board (GlobeNewswire) -5.63%
Feb-28-22 07:30AM	Adamis Pharmaceuticals Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations (GlobeNewswire)
Feb-18-22 04:05PM	Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-07-22 09:17AM	Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19 (GlobeNewswire) +5.81%
Jan-10-22 07:30AM	Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19 (GlobeNewswire) +26.96%
Dec-20-21 10:00AM	Is the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock? (Zacks)
Dec-01-21 07:30AM	Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI (GlobeNewswire) -8.54%
Nov-23-21 02:39PM	Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements (GlobeNewswire) -8.35%
Nov-22-21 04:47PM	Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
01:22PM	Bitcoin mining operation on Navajo land in New Mexico 'positive for the community': Site manager (Yahoo Finance Video)
Nov-19-21 03:34PM	Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update (GlobeNewswire)
Oct-18-21 08:55AM	Adamis Pharmaceuticals stock rockets on heavy volume after opioid overdose treatment gets FDA approval (MarketWatch) +8.85%
07:58AM	Adamis Pharma Stock Jumps as FDA Clears Opioid-Overdose Treatment (TheStreet.com)
07:30AM	Adamis Receives FDA Approval for ZIMHI (GlobeNewswire)
Oct-11-21 05:44PM	East Bay Parkinson's drug maker to be swallowed up in potential $450M deal (American City Business Journals)
Oct-04-21 07:30AM	Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors (GlobeNewswire)
Sep-03-21 12:12PM	Adamis (ADMP) Begins Dosing in COVID Oral Antiviral Study (Zacks)
Sep-02-21 10:56AM	Adamis Stock Jumps As Its Oral COVID-19 Drug Trial Starts Dosing (Benzinga)
07:30AM	Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19 (GlobeNewswire)
Aug-24-21 04:05PM	Adamis Announces Appointment of David C. Benedicto as Chief Financial Officer and Other Events (GlobeNewswire)
01:14PM	Immunology Journal Publishes Data For Adamis' COVID-19 Candidate (Benzinga)
07:30AM	Adamis Pharmaceuticals Announces a Publication with the Human Immune Monitoring Center at Stanford Demonstrating Tempol Significantly Inhibited Multiple Cytokines from COVID-19 Patients Cells (GlobeNewswire)
Aug-19-21 07:30AM	Adamis Highlights National Institutes of Health (NIH) Article Entitled, Tempol: A Potential Home Treatment for COVID-19 (GlobeNewswire)
Aug-04-21 04:05PM	Adamis Announces Agreement to Sell Portion of US Compounding Business (GlobeNewswire)
Jul-19-21 04:05PM	Adamis Announces Results of 2021 Annual Meeting of Stockholders (Business Wire) +12.77%
Jul-13-21 08:00AM	Adamis Urges Stockholders to Vote to Reelect the Companys Board of Directors at Upcoming Annual Meeting on Friday, July 16th (Business Wire)
Jul-01-21 08:00AM	Adamis Sends Letter to Stockholders to Address Jerald A. Hammanns Costly, Distracting and Misguided Campaign (Business Wire)
Jun-28-21 07:00AM	Adamis Sends Letter to Stockholders Regarding Its Strategic Focus on Tempol as a Potentially Potent Treatment for COVID-19 (Business Wire)
Jun-18-21 08:32AM	Are Options Traders Betting on a Big Move in Adamis Pharmaceuticals (ADMP) Stock? (Zacks) -6.36%
Jun-14-21 09:00AM	Adamis Files Definitive Proxy Statement and Sends Letter to Stockholders (Business Wire)
Jun-13-21 02:11PM	Is Adamis Pharmaceuticals Corporation (ADMP) Going to Burn These Hedge Funds? (Insider Monkey)
Jun-11-21 07:30AM	Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19 (GlobeNewswire)
Jun-09-21 07:30AM	Adamis Provides Update on ZIMHI (GlobeNewswire) +6.93%
Jun-07-21 09:51AM	Adamis Pharma Stock Jumps as NIH Sees Promise in Tempol for COVID-19 (Benzinga)
07:30AM	Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19 (GlobeNewswire)
Jun-01-21 07:30AM	Adamis Pharmaceuticals Provides Business Update (GlobeNewswire)
May-28-21 04:04PM	Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from NASDAQ (GlobeNewswire)
May-26-21 03:00PM	Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Adamis Pharmaceuticals Corporation (ADMP) on Behalf of Investors (Business Wire)
11:30AM	The Law Offices of Frank R. Cruz Announces Investigation of Adamis Pharmaceuticals Corporation (ADMP) on Behalf of Investors (Business Wire)
May-25-21 07:42PM	INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Adamis Pharmaceuticals Corporation (ADMP) on Behalf of Investors (Business Wire) -9.40%
02:12PM	Investor Alert: Berman Tabacco Investigates Potential Securities Law Violations By Adamis Pharmaceuticals Corporation (ADMP) In Connection With U.S. Attorney's Criminal Investigation (Newsfile)
May-17-21 04:05PM	Adamis Pharmaceuticals Provides Update on First Quarter 2021 Financial Results Conference Call (GlobeNewswire) +7.06%

DMK Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets. It offers the SYMJEPI Injection for the emergency treatment of allergic reactions. The company was founded in June 2006 and is headquartered in San Diego, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DMK

DMK Pharmaceuticals Corp

Upgrade your FINVIZ experience